Enteris BioPharma, Inc.

Mar 01, 2018

Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 1 Trial of Oral KORSUVA(TM)

Jan 03, 2018

Enteris BioPharma Announces Positive Results from Phase 2a Clinical Trial of Ovarest® (oral leuprolide tablet) for Endometriosis

Oct 31, 2017

Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 1 Study of Peptelligence(TM)-Engineered Oral CR845 in Non-Hemodialysis Chronic Kidney Disease Patients

Sep 19, 2017

Enteris BioPharma to Present at BioPharm America

Aug 24, 2017

Enteris BioPharma Doses First Woman in Phase 2a Clinical Trial of Ovarest(TM) (oral leuprolide tablet) for Endometriosis

Jun 13, 2017

Enteris BioPharma to Present at BIO 2017